Ashland reports fourth quarter and full-year fiscal 2026 results and issues
Ashland reports fourth quarter and full-year fiscal 2026 results and issues outlook for fiscal 2027
Adjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $52 million, or $1.12 per diluted share
Sales volumes rose three percent from the prior-year quarter, led by growth in Life Sciences and Personal Care
Adjusted EBITDA of $121 million, up two percent from the prior-year quarter; strong growth in Life Sciences, Personal Care, and Intermediates was partially offset by lower earnings in Specialty Additives
Cash flows provided by operating activities of $90 million; Ongoing Free Cash Flow 2 of $74 million
Issues outlook for full‑year fiscal 2027 sales of $1,905-$1,975 million and Adjusted EBITDA of $405-$435 million
WILMINGTON, Del., November 3, 2026 – Ashland Inc. (NYSE: ASH) today announced financial results1for the fourth quarter of fiscal year 2026, which ended September 30, 2026, together with its fiscal year 2026 results summary and full- year fiscal 2027 outlook. Ashland, a global additives and specialty ingredients company, holds leadership positions in high-quality, consumer-focused markets including pharmaceuticals, personal care and architectural coatings.
“Ashland closed fiscal 2026 with strong commercial performance across our higher-growth Life Sciences and Personal Care businesses, as well as coatings and performance specialties within Specialty Additives, and improved profitability in Intermediates,” said Guillermo Novo, chair and chief executive officer, Ashland. “Life Sciences delivered four percent sales growth, and pharma achieved its sixth consecutive quarter of year-over-year volume growth, with broad gains across regions and continued momentum from our globalize and innovate strategies. Personal Care generated another quarter of strong performance, with eight percent sales growth, including double-digit growth in biofunctional actives, microbial protection and hair care, and high-single-digit growth in skin care. Specialty Additives delivered nine percent sales growth in coatings and fourteen percent sales growth in performance specialties, reflecting share gains across all regions. These gains were offset by soft end- market demand in energy and resources and lower construction volumes resulting from deliberate portfolio actions.”
"Our globalize and innovate strategies exceeded their full-year targets, driven by deep customer engagement and successful commercialization," said Guillermo Novo, chair and chief executive officer, 1 Ashland. “Despite raw material and freight volatility, our teams executed well, with pricing actions recovering higher raw material costs. We have completed the critical investments needed to support improved productivity at our plants. We also generated healthy cash flow, further strengthening our financial flexibility as we enter fiscal 2027."
Novo continued, "Our priorities are clear: improve operating performance, drive productivity across our network, maintain pricing discipline, build on our commercial momentum and continue to scale our globalize and innovate initiatives. The strategic foundations are in place, and our focus is on execution to deliver improved profitability and long-term value creation."
Fourth-quarter sales were $498 million, up four percent from $478 million in the prior-year quarter. Sales volumes increased three percent, led by Pharma, Personal Care, Coatings and Performance Specialties. Pricing increased two percent, covering raw material cost inflation across all business units. Foreign currency movements reduced sales by approximately $3 million, or one percent.
Net loss was $16 million, compared with net income of $32 million in the prior- year quarter. Loss from continuing operations was $17 million, or ($0.36) per diluted share, compared with income from continuing operations of $33 million, or $0.73 per diluted share, in the prior-year quarter. Adjusted Income from Continuing Operations Excluding Intangibles Amortization Expense was $52 million, up from $50 million, or $1.12 per diluted share versus $1.08 in the prior-year quarter. Adjusted Operating Income was $77 million, up from $71 million in the prior-year quarter. Adjusted EBITDA was $121 million, up two percent from $119 million, and Adjusted EBITDA margin was 24.3 percent compared with 24.9 percent in the prior-year quarter. Double-digit Adjusted EBITDA growth in Life Sciences, Personal Care and Intermediates was partially offset by lower earnings in Specialty Additives, reflecting an unfavorable absorption impact, and higher unallocated corporate expenses. Foreign currency movements reduced Adjusted EBITDA by approximately $2 million.
Average diluted shares outstanding were 46 million in the fourth quarter, unchanged from the prior-year quarter.
Cash flows provided by operating activities were $90 million, up from $40 million in the prior-year quarter, driven primarily by lower working capital. Ongoing Free Cash Flow totaled $74 million versus $52 million in the prior-year quarter, representing Ongoing Free Cash Flow conversion of 61 percent versus 44 percent in the prior-year quarter, primarily reflecting the year-over-year reduction in working capital. 2 Reportable Segment Performance
To aid in the understanding of Ashland’s ongoing business performance, the results of Ashland’s reportable segments are described below on an adjusted basis. In addition, EBITDA and Adjusted EBITDA are reconciled to operating income in Table 4. Free Cash Flow, Ongoing Free Cash Flow and Adjusted Operating Income are reconciled in Table 6 and Adjusted Income from Continuing Operations, Adjusted Diluted Earnings Per Share and Adjusted Diluted Earnings Per Share Excluding Intangible Amortization Expense are reconciled in Table 7 of this news release. These adjusted results are considered non-GAAP financial measures. For a full description of the non-GAAP financial measures used, see the “Use of Non- GAAP Measures” section that further describes these adjustments below.
Sales for the Life Sciences segment totaled $180 million in the fourth quarter, an increase of four percent compared with the prior-year quarter. Performance was driven by higher volumes, led by broad pharma growth across all major regions and technology platforms, including VP&D, cellulosics, injectables and film coatings. Pharma sales increased approximately six percent, representing the sixth consecutive quarter of year-over-year volume growth, supported by continued momentum from Ashland's globalize and innovate strategies. Nutrition sales declined slightly due to lower volumes. Prices increased approximately one percent compared with the prior year and covered cost inflation. Foreign currency movements reduced segment sales by approximately $1 million.
Adjusted Operating Income for the quarter was $50 million, up from $41 million in the prior-year quarter. Adjusted EBITDA totaled $64 million, an increase of 16 percent compared with $55 million in the prior-year quarter, and Adjusted EBITDA margin increased 380 basis points to 35.6 percent, the highest quarterly margin in the segment's history. The year-over-year increase was driven primarily by higher volumes, favorable product mix, pricing and cost performance. Foreign currency movements reduced Adjusted EBITDA by approximately $1 million during the quarter.
Personal Care sales in the fourth quarter were $163 million, an increase of eight percent compared with $151 million in the prior-year quarter. Performance reflected broad-based gains across the portfolio, including double-digit sales growth in biofunctional actives and microbial protection. Care Ingredients delivered strong results, led by double-digit growth in hair care and high- single-digit growth in skin care, while oral care and household sales declined by a low-single-digit percentage in aggregate. Performance was also strong across regions, with year-over-year sales growth in North America, Europe, China, Latin America and Rest of Asia. Prices increased modestly compared with the prior year and covered raw material cost inflation. Foreign currency movements reduced segment sales by approximately $1 million.
Adjusted Operating Income was $35 million, up 25 percent from $28 million in the prior-year quarter. Adjusted EBITDA was $49 million, up 14 percent from $43 million in the prior-year quarter, and Adjusted EBITDA margin increased 160 basis points to 30.1 percent. The year-over-year increase was driven primarily by higher sales volumes, favorable product mix, pricing and cost performance. Foreign currency movements had a negligible impact on Adjusted EBITDA. 3 Specialty Additives
Specialty Additives sales were $131 million in the fourth quarter, in line with the prior-year quarter. Coatings sales increased nine percent and Performance Specialties sales increased fourteen percent, reflecting favorable volumes, pricing and share gains across all regions, including a third consecutive quarter of year-over-year sales growth in China. These gains were offset by soft end-market demand in Energy and Resources and lower Construction volumes resulting from deliberate portfolio actions to prioritize higher-value applications. Prices increased approximately five percent compared with the prior-year quarter, covering raw material cost inflation. Foreign currency movements reduced segment sales by approximately $1 million.
Adjusted Operating Income was $5 million, compared with $12 million in the prior-year quarter, and Adjusted EBITDA was $20 million, down 31 percent from $29 million in the prior-year quarter. The year-over-year decline primarily reflected lower Hopewell productivity and related unfavorable absorption. Key productivity investments are now complete, with the focus on execution to increase production. Favorable price and mix partially offset these pressures. Foreign currency movements reduced Adjusted EBITDA by approximately $1 million.
Intermediates sales totaled $33 million in the fourth quarter, in line with the prior-year quarter. Merchant sales increased four percent to $24 million, offset by a $1 million decline in captive sales to $9 million. Favorable merchant mix, including higher NMP sales, and pricing more than offset lower merchant BDO volumes. Pricing increased approximately five percent compared with the prior- year quarter and covered raw material inflation. Foreign currency movements had a negligible impact on segment sales.
Adjusted Operating Income was $4 million, compared with $2 million in the prior- year quarter. Adjusted EBITDA was $6 million, up 20 percent from $5 million in the prior-year quarter, and Adjusted EBITDA margin increased 300 basis points to 18.2 percent. The year-over-year improvement was driven primarily by favorable merchant mix, pricing and cost performance, partially offset by lower volumes. Foreign currency movements had a negligible impact on Adjusted EBITDA during the quarter.
Unallocated and other expense was $44 million, compared with $11 million in the prior-year quarter. The year-over-year increase primarily reflected higher restructuring charges and a cumulative translation adjustment associated with the liquidation of Ashland’s Argentine entity. Adjusted unallocated and other EBITDA expense was $18 million compared with $13 million in the prior-year quarter, primarily reflecting higher incentive and stock-based compensation expense.
Sales were $1.863 billion, up two percent from $1.824 billion in the prior year. Excluding the impact of the previously announced Avoca divestiture, organic sales increased three percent. Commercial momentum strengthened throughout the year, with second-half sales increasing approximately six percent year over year. Life Sciences benefited from sustained pharma growth, Personal Care delivered broad-based growth across its higher-value businesses, and within Specialty Additives, Coatings and Performance Specialties 4 gained momentum as the year progressed. For the full year, volumes contributed approximately two percent to sales, pricing had a negligible impact, and foreign currency contributed approximately one percent. Pricing strengthened in the second half as actions were taken to offset cost inflation.
Net income was $4 million, compared with a net loss of $845 million in the prior year. Income from continuing operations was $25 million, or $0.55 per diluted share, compared with a loss from continuing operations of $822 million, or ($17.74) per diluted share, in fiscal 2025. The significant year-over-year improvement in reported results primarily reflected the absence of the $706 million non-cash goodwill impairment and $175 million Avoca-related impairment and sale adjustment recognized in fiscal 2025. Adjusted Income from Continuing Operations Excluding Intangibles Amortization Expense was $153 million, or $3.31 per diluted share, compared with $157 million, or $3.38 per diluted share, in the prior year.
Adjusted EBITDA was $385 million, compared with $401 million in fiscal 2025, including a $1 million year-over-year impact from the Avoca divestiture. Life Sciences and Personal Care delivered Adjusted EBITDA and margin growth, supported by resilient demand, favorable mix and strong execution. Within Specialty Additives, strong commercial performance in Coatings and Performance Specialties was more than offset by lower Hopewell productivity and the related unfavorable absorption impact. Intermediates profitability improved as the year progressed, supported by favorable merchant mix, pricing and cost performance. Overall Adjusted EBITDA margin was 20.7 percent, compared with 22.0 percent in fiscal 2025.
Cash flow from operating activities was $385 million, compared with $134 million in the prior year. Ongoing Free Cash Flow was $232 million, compared with $127 million in fiscal 2025. The year-over-year improvement primarily reflected lower working capital, driven by reduced inventory, as well as lower capital expenditures. Ashland ended fiscal 2026 with approximately $480 million of cash, $976 million of total liquidity and net debt of $891 million. Net leverage of 2.3x was within the company's long-term target range, providing significant financial flexibility entering fiscal 2027.
Throughout fiscal 2026, Ashland continued to advance its Execute, Globalize and Innovate priorities, strengthening its operating foundation while expanding opportunities for profitable growth. Execute initiatives delivered benefits across multiple pillars during the year, but Hopewell HEC productivity was below expectations. Globalize generated approximately $26 million of incremental sales, exceeding its fiscal 2026 target of $20 million. Innovate generated approximately $26 million of incremental sales, exceeding its fiscal 2026 target of $15 million. The company continued to advance its longer-term innovation portfolio toward customer validation, commercial launch and scaling. These initiatives position Ashland to deliver improved profitability, cash generation and sustainable long-term growth.
Financial Outlook Ashland is issuing the following guidance for fiscal 2027, reflecting its current expectations for market conditions, business performance and continued execution of its strategic priorities. 5 Full-year fiscal 2027 guidance Sales: $1,905 million to $1,975 million, reflecting growth of approximately two to six percent over the prior year
Ongoing Free Cash Flow Conversion: greater than 40 percent of Adjusted EBITDA, reflecting a modest increase in inventory and capital expenditures of up to approximately $140 million Key planning assumptions Demand environment: the outlook reflects a measured assessment of global demand conditions across Ashland's end markets. Demand in Life Sciences and Personal Care is expected to remain resilient, supported by continued pharma momentum and growth across higher-value Personal Care applications. Within Specialty Additives, Coatings and Performance Specialties are expected to build on recent commercial momentum. Intermediates is expected to benefit from new customer volumes in energy storage.
Commercial execution: Ashland expects continued execution of its globalize and innovate initiatives to support profitable growth. The company remains focused on expanding adoption of higher-value solutions and scaling commercial opportunities across its key end markets.
Pricing and input costs: raw material and freight costs are expected to remain volatile during fiscal 2027, with pricing actions expected to offset anticipated inflation.
Operational performance: the outlook incorporates expected year-over-year benefits from non-recurring events and improved manufacturing productivity. Improving plant operations remains a key priority for fiscal 2027.
Foreign currency: based on recent spot rates, the outlook reflects a stronger U.S. dollar, resulting in estimated headwinds of approximately $20-$25 million to sales and $7-$10 million to Adjusted EBITDA. Fiscal 2027 strategic priority targets Execute: deliver approximately $10 million in net incremental productivity and manufacturing optimization benefits.
Globalize: generate approximately $20 million in incremental sales by scaling biofunctional actives, microbial protection, injectables and tablet coatings through geographic expansion and increased customer penetration.
Innovate: generate $45 million in incremental innovation-driven sales through the commercialization of new technologies, scaling of recently launched solutions and increased customer adoption.
"Our performance improved as the year progressed, reflecting the strength of our strategy and the commitment of our teams," concluded Novo. "Although the external markets remain challenging, we have a resilient portfolio with all businesses well positioned to focus on the factors within our control and deliver profitable growth.” 6 Conference Call Webcast
The company’s live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, November 4, 2026. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website athttp://investor.ashland.com.
To access the call by phone, please go tothis registration linkand you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.
Following the live event, an archived version of the webcast and supporting materials will be available for 12 months athttp://investor.ashland.com.
Ashland believes that by removing the impact of depreciation and amortization and excluding certain non-cash charges, amounts spent on interest and taxes, and certain other charges that are highly variable from year to year, EBITDA, Adjusted EBITDA, EBITDA Margin and Adjusted EBITDA Margin provide Ashland’s investors with performance measures that reflect the impact to operations from trends in changes in sales, margin and operating expenses, providing a perspective not immediately apparent from net income, operating income, net income margin, and operating income margin. The adjustments Ashland makes to derive the non-GAAP measures of EBITDA, Adjusted EBITDA, EBITDA Margin and Adjusted EBITDA Margin exclude items which may cause short-term fluctuations in net income and operating income and which Ashland does not consider to be the fundamental attributes or primary drivers of its business. EBITDA, Adjusted EBITDA, EBITDA Margin, and Adjusted EBITDA Margin provide disclosure on the same basis as that used by Ashland’s management to evaluate financial performance on a consolidated and reportable segment basis and provide consistency in our financial reporting, facilitate internal and external comparisons of Ashland’s historical operating performance and its business units, and provide continuity to investors for comparability purposes. EBITDA Margin and Adjusted EBITDA Margin are defined as EBITDA and Adjusted EBITDA divided by sales for the corresponding period.
Key items, which are set forth on Table 7 of this release, are defined as financial effects from significant transactions that, either by their nature or amount, have caused short-term fluctuations in net income and/or operating income which Ashland does not consider to reflect Ashland’s underlying business performance and trends most accurately. Further, Ashland believes that providing supplemental information that excludes the financial effects of these items in the financial results will enhance the investor’s ability to compare financial performance between reporting periods.
Tax-specific key items, which are set forth on Table 7 of this release, are defined as financial transactions, tax law changes or other matters that fall within the definition of key items as described above. These items relate solely to tax matters and would only be recorded within the income tax caption of the Statement of Consolidated Income. As with all key items, due to their nature, Ashland does not consider the financial effects of these tax-specific key items on net income to be the most accurate reflection of Ashland’s underlying business performance and trends. 7 The Free Cash Flow metrics enable Ashland to provide a better indication of the ongoing cash being generated that is ultimately available for both debt and equity holders as well as other investment opportunities. Unlike cash flow provided by operating activities, Free Cash Flow and Ongoing Free Cash Flow include the impact of capital expenditures from continuing operations and other significant items impacting Free Cash Flow, providing a more complete picture of current and future cash generation. Free Cash Flow, Ongoing Free Cash Flow, and Ongoing Free Cash Flow Conversion are non-GAAP liquidity measures that Ashland believes provide useful information to management and investors about Ashland’s ability to convert Adjusted EBITDA to ongoing Free Cash Flow. These liquidity measures are used regularly by Ashland’s stakeholders and industry peers to measure the efficiency at providing cash from regular business activity. Free Cash Flow, Ongoing Free Cash Flow, and Free Cash Flow Conversion have certain limitations, including that they do not reflect adjustments for certain non- discretionary cash flows such as mandatory debt repayments. The amount of mandatory versus discretionary expenditures can vary significantly between periods.
Adjusted Diluted Earnings Per Share is a performance measure used by Ashland and is defined by Ashland as earnings (loss) from continuing operations, adjusted for identified key items and divided by the number of outstanding diluted shares of common stock. Ashland believes this measure provides investors additional insights into operational performance by providing earnings and diluted earnings per share metrics that exclude the effect of the identified key items and tax specific key items.
The Adjusted Diluted Earnings Per Share Excluding Intangibles Amortization Expense metric enables Ashland to demonstrate the impact of non-cash intangibles amortization expense on earnings per share, in addition to key items previously mentioned. Ashland’s management believes this presentation is helpful to illustrate how previous acquisitions impact applicable period results.
Ashland does not quantitatively reconcile our guidance ranges for our non-GAAP measures to their most comparable GAAP measures in the Financial Outlook section of this news release. The guidance ranges for GAAP and non-GAAP financial measures reflect Ashland’s assessment of potential sources of variability in financial results and are informed by evaluation of multiple scenarios, many of which have interactive effects across several financial statement line items. Providing guidance for individual reconciling items between our non-GAAP financial measures and the comparable GAAP measures would imply a degree of precision and certainty in those reconciling items that is not a consistent reflection of our scenario-based process to prepare our guidance ranges. To the extent that a material change affecting the individual reconciling items between the company’s forward-looking non-GAAP and comparable GAAP financial measures is anticipated, the company has provided qualitative commentary in the Financial Outlook section of this news release for your consideration. However, as the impact of such factors cannot be predicted with a reasonable degree of certainty or precision, a quantitative reconciliation is not available without unreasonable effort.
Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and 8 beverage, personal care and pharmaceuticals. Approximately 2,800 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as “anticipates,” “believes,” “expects,” “estimates,” “is likely,” “predicts,” “projects,” “forecasts,” “objectives,” “may,” “will,” “should,” “plans” and “intends” and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its annual reports, quarterly reports and other filings with the U.S. Securities and Exchange Commission (“SEC”), news releases and other written and oral communications. These forward-looking statements are based on Ashland’s expectations and assumptions, as of the date such statements are made, regarding Ashland’s future operating performance, financial, operating cash flow and liquidity, as well as the economy and other future events or circumstances. These statements include, but are not limited to, expectations regarding the fiscal 2027 financial outlook and the key planning assumptions underlying that outlook, expected improvements in plant reliability and productivity, including the pace of improvement in Hopewell output and the timing of a Specialty Additives margin recovery; anticipated productivity and manufacturing optimization benefits, including those from the HEC and VP&D networks and the small plant consolidation initiative; Ashland’s fiscal 2027 Execute, Globalize and Innovate targets and the advancement of its innovation portfolio and Technology Platforms; Ashland’s commercial momentum and competitive positioning; Ashland’s cash generation and financial flexibility; and Ashland’s ability to deliver improved profitability and create long-term value.
Ashland’s expectations and assumptions include, without limitation, internal forecasts and analyses of current and future market conditions and trends, management plans and strategies, operating efficiencies and economic conditions (such as prices, supply and demand, cost of raw materials, and the ability to recover raw-material cost increases through price increases), and risks and uncertainties associated with the following: Ashland’s aggressive growth goals and the extent to which such goals may be impacted by a failure to optimize our tangible and intangible assets, a failure to identify and integrate acquisition targets, and any unexpected costs and liabilities associated with such acquisitions, and goodwill impairment; business disruptions stemming from natural, operational, and other catastrophic events, including disruptions to supply and logistics functions, manufacturing delays, and information technology system and network failures; climate change and related resource impacts; changes in consumer preferences and a reduction in demand for Ashland’s products; risks inherent in operating a global business, including tariffs and other trade policies, and geopolitical instability and armed conflict; economic downturns and disruptions in the financial markets; Ashland’s substantial indebtedness, including the possibility that such indebtedness and related restrictive covenants may adversely affect our future cash flows, limit our ability to repay debt and obtain future financing, place Ashland at a competitive disadvantage, and make us more vulnerable to interest rate increases; our ability to develop and market new products and remain competitive in the markets in which we operate; our ability to pass increases in the costs of energy and raw materials to customers and to fulfill our contractual requirements with customers and vendors; downward 9 pressures on prices and margins; the ability to attract and retain key employees, including across foreign jurisdictions where employment laws and business and cultural practices may differ, and to provide for effective succession planning; cybersecurity risks, including disruptions to or failures in Ashland’s information technology systems and networks, malicious cyberattacks, the inadvertent or accidental disclosure or loss of proprietary or sensitive information, and cyber risks related to Ashland’s external service providers and other third parties; risks related to Ashland’s use of artificial intelligence, including the potential for flawed or unreliable outputs, and the complexities and uncertainties in the legal and regulatory landscapes; Ashland’s ability to effectively protect and enforce its intellectual property rights; exposure to products liability claims; risks related to compliance with environmental, health, and safety regulations, including the potential for costly litigation, remediation, and settlement actions; exposure to pending and threatened asbestos-related litigation; changes in the legal and regulatory landscapes in which we operate; changes in taxation or adverse tax rulings; and, without limitation, risks and uncertainties affecting Ashland that are described in Ashland’s most recent Annual Report on Form 10-K (including Item 1A Risk Factors) filed with the SEC, which is available on Ashland’s website at http://investor.ashland.com or on the SEC’s website at http://www.sec.gov. Various risks and uncertainties may cause actual results to differ materially from those stated, projected or implied by any forward-looking statements. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update any forward-looking statements made in this news release whether as a result of new information, future events or otherwise. 1 Financial results are preliminary until Ashland’s Form 10-K is filed with the U.S. Securities and Exchange Commission. 2 The Ongoing Free Cash Flow metric excludes the impact of inflows and outflows from U.S. and Foreign Accounts Receivable Sales Program and payments related to restructuring and environmental and litigation-related matters in both the current-year and prior-year periods. ™ Trademark, Ashland or its subsidiaries, registered in various countries. FOR FURTHER INFORMATION:
Investor Relations: Media Relations: Sandy Klugman Carolmarie C. Brown +1 (302) 594-7777 +1 (302) 995-3158 [email protected] [email protected]
Ashland Inc. and Consolidated Subsidiaries STATEMENTS OF CONSOLIDATED INCOME (LOSS)(In Table 1 millions except per share data - preliminary and unaudited)
(a) Zero denotes less than $1 million of activity. (b) As a result of the loss from continuing operations for both the three months ended September 30, 2026 and year ended September 30, 2025, the effect of the share-based awards convertible to common shares would be anti-dilutive. In accordance with U.S. GAAP, these shares have been excluded from the diluted earnings (loss) per share calculation for the period. 11
Ashland Inc. and Consolidated Subsidiaries CONDENSED CONSOLIDATED BALANCE SHEETS(In millions Table 2 - preliminary and unaudited)
ASSETS September 30 September 30 Current assets 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash equivalents $ 480 $ 215 Accounts receivable, net 266 242 Inventories 482 568 Other assets 108 180 Total current assets 1,336 1,205 Noncurrent assets Property, plant and equipment Cost 3,304 3,355 Accumulated depreciation 2,170 2,154 Net property, plant and 1,134 1,201 equipment Goodwill 698 705 Intangibles, net 498 563 Operating lease assets, net 99 103 Restricted investments 248 297 Asbestos insurance 137 127 receivable, net Deferred income taxes 138 157 Other assets 239 253 Total noncurrent assets 3,191 3,406 Total assets $ 4,527 $ 4,611 LIABILITIES AND EQUITY Current liabilities Trade and other payables $ 210 $ 189 Accrued expenses and other 220 213 liabilities Current portion of long-term 4 - debt Current operating lease 18 21 obligations Total current liabilities 452 423 Noncurrent liabilities Long-term debt 1,367 1,384 Asbestos litigation reserves 385 389 Deferred income taxes 24 31 Employee benefit obligations 77 96 Operating lease obligations 83 85 Other liabilities 291 299 Total noncurrent liabilities 2,227 2,284 Equity 1,848 1,904 Total liabilities and equity $ 4,527 $ 4,611
Ashland Inc. and Consolidated Subsidiaries STATEMENTS OF CONSOLIDATED CASH FLOWS(In millions Table 3 - preliminary and unaudited)
(a) Excludes changes resulting from operations sold. (b) Zero denotes less than $1 million of activity. 13
Ashland Inc. and Consolidated Subsidiaries RECONCILIATION OF NON-GAAP DATA - ADJUSTED Table 4 EBITDA(In millions - preliminary and unaudited)
Three months ended Adjusted EBITDA - Ashland September 30 Inc. 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net (loss) income $ (16 ) $ 32 Income tax expense 26 31 Net interest and other 21 - income Depreciation and 45 49 amortization(a) EBITDA 76 112 (Income) loss from discontinued (1 ) 1 operations, net of income taxes Gain on pension and other postretirement (2 ) (4 ) plan remeasurements Operating key items (see 48 10 Table 5) Adjusted EBITDA $ 121 $ 119 Adjusted EBITDA - Life Sciences Operating income $ 33 $ 39 Add: Depreciation and 14 14 amortization Operating key items (see 17 2 Table 5) Adjusted EBITDA $ 64 $ 55 Adjusted EBITDA - Personal Care Operating income $ 35 $ 26 Add: Depreciation and 14 15 amortization(a) Operating key items (see - 2 Table 5) Adjusted EBITDA $ 49 $ 43 Adjusted EBITDA - Specialty Additives Operating income $ 1 $ 5 Add: Depreciation and 15 17 amortization Operating key items (see 4 7 Table 5) Adjusted EBITDA $ 20 $ 29 Adjusted EBITDA - Intermediates Operating income $ 4 $ 2 Add: Depreciation and 2 3 amortization Adjusted EBITDA $ 6 $ 5
(a) Depreciation and amortization excludes accelerated depreciation expense of $1 million for Personal Care for the three months ended September 30, 2025, which is included as a key item within this table as a component of Adjusted EBITDA. 14
Ashland Inc. and Consolidated Subsidiaries SEGMENT COMPONENTS OF KEY ITEMS FOR APPLICABLE Table 5 CONSOLIDATED INCOME (LOSS) STATEMENT CAPTIONS(In millions - preliminary and unaudited)
(a) Represents the tax effect of the key items that are previously identified above. (b) Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. See Table 7 for additional information. 15
Ashland Inc. and Consolidated Subsidiaries RECONCILIATION OF CERTAIN NON-GAAP DATA(In Table 6 millions - preliminary and unaudited)
(a) Represents receipt of tax refund related to the capital loss carryback from the Nutraceutical business sale. (b) Represents activity associated with the U.S. Accounts Receivable Sales Program impacting each period presented. (c) Represents activity associated with the Foreign Accounts Receivable Sales Program impacting each period presented. (d) Restructuring payments incurred during each period presented. (e) Represents cash outflows associated with environmental and related litigation payments which will be reimbursed by the Environmental trust. (f) See Adjusted EBITDA reconciliation. (g) Operating Cash Flow Conversion is defined as Cash flows provided by operating activities from continuing operations divided by net (loss) income. (h) Ongoing Free Cash Flow Conversion is defined as Ongoing Free Cash Flow divided by Adjusted EBITDA.
Ashland Inc. and Consolidated Subsidiaries RECONCILIATION OF CERTAIN NON-GAAP DATA(In Table 7 millions except per share data - preliminary and unaudited)
(a) Represents the tax effect of the key items that are previously identified above. (b) Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. These tax specific key items included the following: - Valuation allowance: Includes the impact from the release of certain foreign tax credit valuation allowances. - Other and tax reform: Includes the impact from the remeasurement of foreign deferred tax balances resulting from the impact from rate changes for foreign jurisdictions and other tax law changes enacted during the year ended September 30, 2025. (c) Intangibles amortization expense adjustment (net of tax) tax rates were 20% for the three months and years ended September 30, 2026 and 2025. 17
Ashland Inc. and Consolidated Subsidiaries RECONCILIATION OF CERTAIN NON-GAAP DATA(In Table 7 (Continued) millions except per share data - preliminary and unaudited)
(a) Represents the tax effect of the key items that are previously identified above. (b) Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. These tax specific key items included the following: - Valuation allowance: Includes the impact from the release of certain foreign tax credit valuation allowances. - Other and tax reform: Includes the impact from the remeasurement of foreign deferred tax balances resulting from the impact from rate changes for foreign jurisdictions and other tax law changes enacted during the year ended September 30, 2025. (c) Intangibles amortization expense adjustment (net of tax) tax rates were 20% for the three months and years ended September 30, 2026 and 2025. 18
Ashland Inc. and Consolidated Subsidiaries RECONCILIATION OF CERTAIN NON-GAAP DATA(In Table 8 millions - preliminary and unaudited)
Year ended ────────────────────────────────────────────────────────────────────────────── September 30 Adjusted EBITDA - Ashland Inc. 2026 2025 Net income (loss) $ 4 $ (845 ) Income tax expense 44 13 Net interest and other expense 40 33 Depreciation and 180 198 amortization(a) EBITDA 268 (601 ) Income (loss) from discontinued 21 23 operations, net of income taxes Key items included in EBITDA: Environmental reserve 33 34 adjustments Restructuring, separation and other 23 22 costs Other plant optimization costs 21 22 Asset impairments 18 - Argentina liquidation cumulative 13 - translation adjustment Accelerated depreciation 5 41 Goodwill impairment - 706 Avoca business impairment and - 175 sale Nutraceutical business impairment and - 1 sale Held for sale depreciation and - (2 ) amortization Income on divestitures, net (2 ) (14 ) Tax credit (8 ) (3 ) Gain on pension and other postretirement (7 ) (3 ) plan remeasurements(b) Adjusted EBITDA(b) $ 385 $ 401
(a) Depreciation and amortization excludes accelerated depreciation of $21 million for Life Sciences for the year ended September 30, 2025, $1 million for Personal Care for the year ended September 30, 2026, $3 million and $19 million for Specialty Additives for the years ended September 30, 2026 and 2025, respectively, and $1 million for Unallocated and other for the year ended September 30, 2026, which are included as a key item within this table as a component of Adjusted EBITDA. Depreciation and amortization includes $2 million for Personal Care associated with the Avoca business for the year ended September 30, 2025, which is included as a key item within this table as a component of Adjusted EBITDA. (b) Includes $5 million and $7 million of net periodic loss recognized ratably through the years ended September 30, 2026 and 2025, respectively. These costs are comprised of service cost, interest cost, expected return on plan assets, and amortization of prior service credit. 19
Full text with the tables
Exhibit 99.1
Ashland reports fourth quarter and full-year fiscal 2026 results and issues
outlook for fiscal 2027
Sales of $498 million, up four percent from the prior-year quarter
Loss from continuing operations of $17 million, or ($0.36) per diluted share
Adjusted Income from Continuing Operations Excluding Intangibles Amortization
Expense of $52 million, or $1.12 per diluted share
Net loss of $16 million, or ($0.35) per diluted share
Sales volumes rose three percent from the prior-year quarter, led by growth in
Life Sciences and Personal Care
Adjusted EBITDA of $121 million, up two percent from the prior-year quarter;
strong growth in Life Sciences, Personal Care, and Intermediates was partially
offset by lower earnings in Specialty Additives
Cash flows provided by operating activities of $90 million; Ongoing Free Cash
Flow 2 of $74 million
Issues outlook for full‑year fiscal 2027 sales of $1,905-$1,975 million and
Adjusted EBITDA of $405-$435 million
WILMINGTON, Del., November 3, 2026 – Ashland Inc. (NYSE: ASH) today announced
financial results1for the fourth quarter of fiscal year 2026, which ended
September 30, 2026, together with its fiscal year 2026 results summary and full-
year fiscal 2027 outlook. Ashland, a global additives and specialty ingredients
company, holds leadership positions in high-quality, consumer-focused markets
including pharmaceuticals, personal care and architectural coatings.
“Ashland closed fiscal 2026 with strong commercial performance across our
higher-growth Life Sciences and Personal Care businesses, as well as coatings
and performance specialties within Specialty Additives, and improved
profitability in Intermediates,” said Guillermo Novo, chair and chief executive
officer, Ashland. “Life Sciences delivered four percent sales growth, and pharma
achieved its sixth consecutive quarter of year-over-year volume growth, with
broad gains across regions and continued momentum from our globalize and
innovate strategies. Personal Care generated another quarter of strong
performance, with eight percent sales growth, including double-digit growth in
biofunctional actives, microbial protection and hair care, and high-single-digit
growth in skin care. Specialty Additives delivered nine percent sales growth in
coatings and fourteen percent sales growth in performance specialties,
reflecting share gains across all regions. These gains were offset by soft end-
market demand in energy and resources and lower construction volumes resulting
from deliberate portfolio actions.”
"Our globalize and innovate strategies exceeded their full-year targets, driven
by deep customer engagement and successful commercialization," said Guillermo
Novo, chair and chief executive officer,
1
Ashland. “Despite raw material and freight volatility, our teams executed well,
with pricing actions recovering higher raw material costs. We have completed the
critical investments needed to support improved productivity at our plants. We
also generated healthy cash flow, further strengthening our financial
flexibility as we enter fiscal 2027."
Novo continued, "Our priorities are clear: improve operating performance, drive
productivity across our network, maintain pricing discipline, build on our
commercial momentum and continue to scale our globalize and innovate
initiatives. The strategic foundations are in place, and our focus is on
execution to deliver improved profitability and long-term value creation."
Fourth-quarter sales were $498 million, up four percent from $478 million in the
prior-year quarter. Sales volumes increased three percent, led by Pharma,
Personal Care, Coatings and Performance Specialties. Pricing increased two
percent, covering raw material cost inflation across all business units. Foreign
currency movements reduced sales by approximately $3 million, or one percent.
Net loss was $16 million, compared with net income of $32 million in the prior-
year quarter. Loss from continuing operations was $17 million, or ($0.36) per
diluted share, compared with income from continuing operations of $33 million,
or $0.73 per diluted share, in the prior-year quarter. Adjusted Income from
Continuing Operations Excluding Intangibles Amortization Expense was $52
million, up from $50 million, or $1.12 per diluted share versus $1.08 in the
prior-year quarter. Adjusted Operating Income was $77 million, up from $71
million in the prior-year quarter. Adjusted EBITDA was $121 million, up two
percent from $119 million, and Adjusted EBITDA margin was 24.3 percent compared
with 24.9 percent in the prior-year quarter. Double-digit Adjusted EBITDA growth
in Life Sciences, Personal Care and Intermediates was partially offset by lower
earnings in Specialty Additives, reflecting an unfavorable absorption impact,
and higher unallocated corporate expenses. Foreign currency movements reduced
Adjusted EBITDA by approximately $2 million.
Average diluted shares outstanding were 46 million in the fourth quarter,
unchanged from the prior-year quarter.
Cash flows provided by operating activities were $90 million, up from $40
million in the prior-year quarter, driven primarily by lower working capital.
Ongoing Free Cash Flow totaled $74 million versus $52 million in the prior-year
quarter, representing Ongoing Free Cash Flow conversion of 61 percent versus 44
percent in the prior-year quarter, primarily reflecting the year-over-year
reduction in working capital.
2
Reportable Segment Performance
To aid in the understanding of Ashland’s ongoing business performance, the
results of Ashland’s reportable segments are described below on an adjusted
basis. In addition, EBITDA and Adjusted EBITDA are reconciled to operating
income in Table 4. Free Cash Flow, Ongoing Free Cash Flow and Adjusted Operating
Income are reconciled in Table 6 and Adjusted Income from Continuing Operations,
Adjusted Diluted Earnings Per Share and Adjusted Diluted Earnings Per Share
Excluding Intangible Amortization Expense are reconciled in Table 7 of this news
release. These adjusted results are considered non-GAAP financial measures. For
a full description of the non-GAAP financial measures used, see the “Use of Non-
GAAP Measures” section that further describes these adjustments below.
Life Sciences
Sales for the Life Sciences segment totaled $180 million in the fourth quarter,
an increase of four percent compared with the prior-year quarter. Performance
was driven by higher volumes, led by broad pharma growth across all major
regions and technology platforms, including VP&D, cellulosics, injectables and
film coatings. Pharma sales increased approximately six percent, representing
the sixth consecutive quarter of year-over-year volume growth, supported by
continued momentum from Ashland's globalize and innovate strategies. Nutrition
sales declined slightly due to lower volumes. Prices increased approximately one
percent compared with the prior year and covered cost inflation. Foreign
currency movements reduced segment sales by approximately $1 million.
Adjusted Operating Income for the quarter was $50 million, up from $41 million
in the prior-year quarter. Adjusted EBITDA totaled $64 million, an increase of
16 percent compared with $55 million in the prior-year quarter, and Adjusted
EBITDA margin increased 380 basis points to 35.6 percent, the highest quarterly
margin in the segment's history. The year-over-year increase was driven
primarily by higher volumes, favorable product mix, pricing and cost
performance. Foreign currency movements reduced Adjusted EBITDA by approximately
$1 million during the quarter.
Personal Care
Personal Care sales in the fourth quarter were $163 million, an increase of
eight percent compared with $151 million in the prior-year quarter. Performance
reflected broad-based gains across the portfolio, including double-digit sales
growth in biofunctional actives and microbial protection. Care Ingredients
delivered strong results, led by double-digit growth in hair care and high-
single-digit growth in skin care, while oral care and household sales declined
by a low-single-digit percentage in aggregate. Performance was also strong
across regions, with year-over-year sales growth in North America, Europe,
China, Latin America and Rest of Asia. Prices increased modestly compared with
the prior year and covered raw material cost inflation. Foreign currency
movements reduced segment sales by approximately $1 million.
Adjusted Operating Income was $35 million, up 25 percent from $28 million in the
prior-year quarter. Adjusted EBITDA was $49 million, up 14 percent from $43
million in the prior-year quarter, and Adjusted EBITDA margin increased 160
basis points to 30.1 percent. The year-over-year increase was driven primarily
by higher sales volumes, favorable product mix, pricing and cost performance.
Foreign currency movements had a negligible impact on Adjusted EBITDA.
3
Specialty Additives
Specialty Additives sales were $131 million in the fourth quarter, in line with
the prior-year quarter. Coatings sales increased nine percent and Performance
Specialties sales increased fourteen percent, reflecting favorable volumes,
pricing and share gains across all regions, including a third consecutive
quarter of year-over-year sales growth in China. These gains were offset by soft
end-market demand in Energy and Resources and lower Construction volumes
resulting from deliberate portfolio actions to prioritize higher-value
applications. Prices increased approximately five percent compared with the
prior-year quarter, covering raw material cost inflation. Foreign currency
movements reduced segment sales by approximately $1 million.
Adjusted Operating Income was $5 million, compared with $12 million in the
prior-year quarter, and Adjusted EBITDA was $20 million, down 31 percent from
$29 million in the prior-year quarter. The year-over-year decline primarily
reflected lower Hopewell productivity and related unfavorable absorption. Key
productivity investments are now complete, with the focus on execution to
increase production. Favorable price and mix partially offset these pressures.
Foreign currency movements reduced Adjusted EBITDA by approximately $1 million.
Intermediates
Intermediates sales totaled $33 million in the fourth quarter, in line with the
prior-year quarter. Merchant sales increased four percent to $24 million, offset
by a $1 million decline in captive sales to $9 million. Favorable merchant mix,
including higher NMP sales, and pricing more than offset lower merchant BDO
volumes. Pricing increased approximately five percent compared with the prior-
year quarter and covered raw material inflation. Foreign currency movements had
a negligible impact on segment sales.
Adjusted Operating Income was $4 million, compared with $2 million in the prior-
year quarter. Adjusted EBITDA was $6 million, up 20 percent from $5 million in
the prior-year quarter, and Adjusted EBITDA margin increased 300 basis points to
18.2 percent. The year-over-year improvement was driven primarily by favorable
merchant mix, pricing and cost performance, partially offset by lower volumes.
Foreign currency movements had a negligible impact on Adjusted EBITDA during the
quarter.
Unallocated & Other
Unallocated and other expense was $44 million, compared with $11 million in the
prior-year quarter. The year-over-year increase primarily reflected higher
restructuring charges and a cumulative translation adjustment associated with
the liquidation of Ashland’s Argentine entity. Adjusted unallocated and other
EBITDA expense was $18 million compared with $13 million in the prior-year
quarter, primarily reflecting higher incentive and stock-based compensation
expense.
Fiscal Year 2026 Results Summary
Sales were $1.863 billion, up two percent from $1.824 billion in the prior year.
Excluding the impact of the previously announced Avoca divestiture, organic
sales increased three percent. Commercial momentum strengthened throughout the
year, with second-half sales increasing approximately six percent year over
year. Life Sciences benefited from sustained pharma growth, Personal Care
delivered broad-based growth across its higher-value businesses, and within
Specialty Additives, Coatings and Performance Specialties
4
gained momentum as the year progressed. For the full year, volumes contributed
approximately two percent to sales, pricing had a negligible impact, and foreign
currency contributed approximately one percent. Pricing strengthened in the
second half as actions were taken to offset cost inflation.
Net income was $4 million, compared with a net loss of $845 million in the prior
year. Income from continuing operations was $25 million, or $0.55 per diluted
share, compared with a loss from continuing operations of $822 million, or
($17.74) per diluted share, in fiscal 2025. The significant year-over-year
improvement in reported results primarily reflected the absence of the $706
million non-cash goodwill impairment and $175 million Avoca-related impairment
and sale adjustment recognized in fiscal 2025. Adjusted Income from Continuing
Operations Excluding Intangibles Amortization Expense was $153 million, or $3.31
per diluted share, compared with $157 million, or $3.38 per diluted share, in
the prior year.
Adjusted EBITDA was $385 million, compared with $401 million in fiscal 2025,
including a $1 million year-over-year impact from the Avoca divestiture. Life
Sciences and Personal Care delivered Adjusted EBITDA and margin growth,
supported by resilient demand, favorable mix and strong execution. Within
Specialty Additives, strong commercial performance in Coatings and Performance
Specialties was more than offset by lower Hopewell productivity and the related
unfavorable absorption impact. Intermediates profitability improved as the year
progressed, supported by favorable merchant mix, pricing and cost performance.
Overall Adjusted EBITDA margin was 20.7 percent, compared with 22.0 percent in
fiscal 2025.
Cash flow from operating activities was $385 million, compared with $134 million
in the prior year. Ongoing Free Cash Flow was $232 million, compared with $127
million in fiscal 2025. The year-over-year improvement primarily reflected lower
working capital, driven by reduced inventory, as well as lower capital
expenditures. Ashland ended fiscal 2026 with approximately $480 million of cash,
$976 million of total liquidity and net debt of $891 million. Net leverage of
2.3x was within the company's long-term target range, providing significant
financial flexibility entering fiscal 2027.
Throughout fiscal 2026, Ashland continued to advance its Execute, Globalize and
Innovate priorities, strengthening its operating foundation while expanding
opportunities for profitable growth. Execute initiatives delivered benefits
across multiple pillars during the year, but Hopewell HEC productivity was below
expectations. Globalize generated approximately $26 million of incremental
sales, exceeding its fiscal 2026 target of $20 million. Innovate generated
approximately $26 million of incremental sales, exceeding its fiscal 2026 target
of $15 million. The company continued to advance its longer-term innovation
portfolio toward customer validation, commercial launch and scaling. These
initiatives position Ashland to deliver improved profitability, cash generation
and sustainable long-term growth.
Financial Outlook
Ashland is issuing the following guidance for fiscal 2027, reflecting its
current expectations for market conditions, business performance and continued
execution of its strategic priorities.
5
Full-year fiscal 2027 guidance
Sales: $1,905 million to $1,975 million, reflecting growth of approximately two
to six percent over the prior year
Adjusted EBITDA: $405 million to $435 million
Ongoing Free Cash Flow Conversion: greater than 40 percent of Adjusted EBITDA,
reflecting a modest increase in inventory and capital expenditures of up to
approximately $140 million
Key planning assumptions
Demand environment: the outlook reflects a measured assessment of global demand
conditions across Ashland's end markets. Demand in Life Sciences and Personal
Care is expected to remain resilient, supported by continued pharma momentum and
growth across higher-value Personal Care applications. Within Specialty
Additives, Coatings and Performance Specialties are expected to build on recent
commercial momentum. Intermediates is expected to benefit from new customer
volumes in energy storage.
Commercial execution: Ashland expects continued execution of its globalize and
innovate initiatives to support profitable growth. The company remains focused
on expanding adoption of higher-value solutions and scaling commercial
opportunities across its key end markets.
Pricing and input costs: raw material and freight costs are expected to remain
volatile during fiscal 2027, with pricing actions expected to offset anticipated
inflation.
Operational performance: the outlook incorporates expected year-over-year
benefits from non-recurring events and improved manufacturing productivity.
Improving plant operations remains a key priority for fiscal 2027.
Foreign currency: based on recent spot rates, the outlook reflects a stronger
U.S. dollar, resulting in estimated headwinds of approximately $20-$25 million
to sales and $7-$10 million to Adjusted EBITDA.
Fiscal 2027 strategic priority targets
Execute: deliver approximately $10 million in net incremental productivity and
manufacturing optimization benefits.
Globalize: generate approximately $20 million in incremental sales by scaling
biofunctional actives, microbial protection, injectables and tablet coatings
through geographic expansion and increased customer penetration.
Innovate: generate $45 million in incremental innovation-driven sales through
the commercialization of new technologies, scaling of recently launched
solutions and increased customer adoption.
"Our performance improved as the year progressed, reflecting the strength of our
strategy and the commitment of our teams," concluded Novo. "Although the
external markets remain challenging, we have a resilient portfolio with all
businesses well positioned to focus on the factors within our control and
deliver profitable growth.”
6
Conference Call Webcast
The company’s live webcast with securities analysts will include an executive
summary and detailed remarks. The live webcast will take place at 9 a.m. ET on
Wednesday, November 4, 2026. Simultaneously, the company will post a slide
presentation in the Investor Relations section of its website
athttp://investor.ashland.com.
To access the call by phone, please go tothis registration linkand you will be
provided with dial-in details. To avoid delays, we encourage participants to
dial into the conference call fifteen minutes ahead of the scheduled start time.
Following the live event, an archived version of the webcast and supporting
materials will be available for 12 months athttp://investor.ashland.com.
Use of Non-GAAP Measures
Ashland believes that by removing the impact of depreciation and amortization
and excluding certain non-cash charges, amounts spent on interest and taxes, and
certain other charges that are highly variable from year to year, EBITDA,
Adjusted EBITDA, EBITDA Margin and Adjusted EBITDA Margin provide Ashland’s
investors with performance measures that reflect the impact to operations from
trends in changes in sales, margin and operating expenses, providing a
perspective not immediately apparent from net income, operating income, net
income margin, and operating income margin. The adjustments Ashland makes to
derive the non-GAAP measures of EBITDA, Adjusted EBITDA, EBITDA Margin and
Adjusted EBITDA Margin exclude items which may cause short-term fluctuations in
net income and operating income and which Ashland does not consider to be the
fundamental attributes or primary drivers of its business. EBITDA, Adjusted
EBITDA, EBITDA Margin, and Adjusted EBITDA Margin provide disclosure on the same
basis as that used by Ashland’s management to evaluate financial performance on
a consolidated and reportable segment basis and provide consistency in our
financial reporting, facilitate internal and external comparisons of Ashland’s
historical operating performance and its business units, and provide continuity
to investors for comparability purposes. EBITDA Margin and Adjusted EBITDA
Margin are defined as EBITDA and Adjusted EBITDA divided by sales for the
corresponding period.
Key items, which are set forth on Table 7 of this release, are defined as
financial effects from significant transactions that, either by their nature or
amount, have caused short-term fluctuations in net income and/or operating
income which Ashland does not consider to reflect Ashland’s underlying business
performance and trends most accurately. Further, Ashland believes that providing
supplemental information that excludes the financial effects of these items in
the financial results will enhance the investor’s ability to compare financial
performance between reporting periods.
Tax-specific key items, which are set forth on Table 7 of this release, are
defined as financial transactions, tax law changes or other matters that fall
within the definition of key items as described above. These items relate solely
to tax matters and would only be recorded within the income tax caption of the
Statement of Consolidated Income. As with all key items, due to their nature,
Ashland does not consider the financial effects of these tax-specific key items
on net income to be the most accurate reflection of Ashland’s underlying
business performance and trends.
7
The Free Cash Flow metrics enable Ashland to provide a better indication of the
ongoing cash being generated that is ultimately available for both debt and
equity holders as well as other investment opportunities. Unlike cash flow
provided by operating activities, Free Cash Flow and Ongoing Free Cash Flow
include the impact of capital expenditures from continuing operations and other
significant items impacting Free Cash Flow, providing a more complete picture of
current and future cash generation. Free Cash Flow, Ongoing Free Cash Flow, and
Ongoing Free Cash Flow Conversion are non-GAAP liquidity measures that Ashland
believes provide useful information to management and investors about Ashland’s
ability to convert Adjusted EBITDA to ongoing Free Cash Flow. These liquidity
measures are used regularly by Ashland’s stakeholders and industry peers to
measure the efficiency at providing cash from regular business activity. Free
Cash Flow, Ongoing Free Cash Flow, and Free Cash Flow Conversion have certain
limitations, including that they do not reflect adjustments for certain non-
discretionary cash flows such as mandatory debt repayments. The amount of
mandatory versus discretionary expenditures can vary significantly between
periods.
Adjusted Diluted Earnings Per Share is a performance measure used by Ashland and
is defined by Ashland as earnings (loss) from continuing operations, adjusted
for identified key items and divided by the number of outstanding diluted shares
of common stock. Ashland believes this measure provides investors additional
insights into operational performance by providing earnings and diluted earnings
per share metrics that exclude the effect of the identified key items and tax
specific key items.
The Adjusted Diluted Earnings Per Share Excluding Intangibles Amortization
Expense metric enables Ashland to demonstrate the impact of non-cash intangibles
amortization expense on earnings per share, in addition to key items previously
mentioned. Ashland’s management believes this presentation is helpful to
illustrate how previous acquisitions impact applicable period results.
Ashland does not quantitatively reconcile our guidance ranges for our non-GAAP
measures to their most comparable GAAP measures in the Financial Outlook section
of this news release. The guidance ranges for GAAP and non-GAAP financial
measures reflect Ashland’s assessment of potential sources of variability in
financial results and are informed by evaluation of multiple scenarios, many of
which have interactive effects across several financial statement line items.
Providing guidance for individual reconciling items between our non-GAAP
financial measures and the comparable GAAP measures would imply a degree of
precision and certainty in those reconciling items that is not a consistent
reflection of our scenario-based process to prepare our guidance ranges. To the
extent that a material change affecting the individual reconciling items between
the company’s forward-looking non-GAAP and comparable GAAP financial measures is
anticipated, the company has provided qualitative commentary in the Financial
Outlook section of this news release for your consideration. However, as the
impact of such factors cannot be predicted with a reasonable degree of certainty
or precision, a quantitative reconciliation is not available without
unreasonable effort.
About Ashland
Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company
with a conscious and proactive mindset for environmental, social and governance
(ESG). The company serves customers in a wide range of consumer and industrial
markets, including architectural coatings, construction, energy, food and
8
beverage, personal care and pharmaceuticals. Approximately 2,800 passionate,
tenacious solvers – from renowned scientists and research chemists to talented
engineers and plant operators – thrive on developing practical, innovative and
elegant solutions to complex problems for customers in more than 100 countries.
Visit ashland.com and ashland.com/ESG to learn more.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended and Section 21E of the
Securities Exchange Act of 1934, as amended. Ashland has identified some of
these forward-looking statements with words such as “anticipates,” “believes,”
“expects,” “estimates,” “is likely,” “predicts,” “projects,” “forecasts,”
“objectives,” “may,” “will,” “should,” “plans” and “intends” and the negative of
these words or other comparable terminology. Ashland may from time to time make
forward-looking statements in its annual reports, quarterly reports and other
filings with the U.S. Securities and Exchange Commission (“SEC”), news releases
and other written and oral communications. These forward-looking statements are
based on Ashland’s expectations and assumptions, as of the date such statements
are made, regarding Ashland’s future operating performance, financial, operating
cash flow and liquidity, as well as the economy and other future events or
circumstances. These statements include, but are not limited to, expectations
regarding the fiscal 2027 financial outlook and the key planning assumptions
underlying that outlook, expected improvements in plant reliability and
productivity, including the pace of improvement in Hopewell output and the
timing of a Specialty Additives margin recovery; anticipated productivity and
manufacturing optimization benefits, including those from the HEC and VP&D
networks and the small plant consolidation initiative; Ashland’s fiscal 2027
Execute, Globalize and Innovate targets and the advancement of its innovation
portfolio and Technology Platforms; Ashland’s commercial momentum and
competitive positioning; Ashland’s cash generation and financial flexibility;
and Ashland’s ability to deliver improved profitability and create long-term
value.
Ashland’s expectations and assumptions include, without limitation, internal
forecasts and analyses of current and future market conditions and trends,
management plans and strategies, operating efficiencies and economic conditions
(such as prices, supply and demand, cost of raw materials, and the ability to
recover raw-material cost increases through price increases), and risks and
uncertainties associated with the following: Ashland’s aggressive growth goals
and the extent to which such goals may be impacted by a failure to optimize our
tangible and intangible assets, a failure to identify and integrate acquisition
targets, and any unexpected costs and liabilities associated with such
acquisitions, and goodwill impairment; business disruptions stemming from
natural, operational, and other catastrophic events, including disruptions to
supply and logistics functions, manufacturing delays, and information technology
system and network failures; climate change and related resource impacts;
changes in consumer preferences and a reduction in demand for Ashland’s
products; risks inherent in operating a global business, including tariffs and
other trade policies, and geopolitical instability and armed conflict; economic
downturns and disruptions in the financial markets; Ashland’s substantial
indebtedness, including the possibility that such indebtedness and related
restrictive covenants may adversely affect our future cash flows, limit our
ability to repay debt and obtain future financing, place Ashland at a
competitive disadvantage, and make us more vulnerable to interest rate
increases; our ability to develop and market new products and remain competitive
in the markets in which we operate; our ability to pass increases in the costs
of energy and raw materials to customers and to fulfill our contractual
requirements with customers and vendors; downward
9
pressures on prices and margins; the ability to attract and retain key
employees, including across foreign jurisdictions where employment laws and
business and cultural practices may differ, and to provide for effective
succession planning; cybersecurity risks, including disruptions to or failures
in Ashland’s information technology systems and networks, malicious
cyberattacks, the inadvertent or accidental disclosure or loss of proprietary or
sensitive information, and cyber risks related to Ashland’s external service
providers and other third parties; risks related to Ashland’s use of artificial
intelligence, including the potential for flawed or unreliable outputs, and the
complexities and uncertainties in the legal and regulatory landscapes; Ashland’s
ability to effectively protect and enforce its intellectual property rights;
exposure to products liability claims; risks related to compliance with
environmental, health, and safety regulations, including the potential for
costly litigation, remediation, and settlement actions; exposure to pending and
threatened asbestos-related litigation; changes in the legal and regulatory
landscapes in which we operate; changes in taxation or adverse tax rulings; and,
without limitation, risks and uncertainties affecting Ashland that are described
in Ashland’s most recent Annual Report on Form 10-K (including Item 1A Risk
Factors) filed with the SEC, which is available on Ashland’s website at
http://investor.ashland.com or on the SEC’s website at http://www.sec.gov.
Various risks and uncertainties may cause actual results to differ materially
from those stated, projected or implied by any forward-looking statements.
Ashland believes its expectations and assumptions are reasonable, but there can
be no assurance that the expectations reflected herein will be achieved. Unless
legally required, Ashland undertakes no obligation to update any forward-looking
statements made in this news release whether as a result of new information,
future events or otherwise. 1 Financial results are preliminary until Ashland’s
Form 10-K is filed with the U.S. Securities and Exchange Commission. 2 The
Ongoing Free Cash Flow metric excludes the impact of inflows and outflows from
U.S. and Foreign Accounts Receivable Sales Program and payments related to
restructuring and environmental and litigation-related matters in both the
current-year and prior-year periods. ™ Trademark, Ashland or its subsidiaries,
registered in various countries. FOR FURTHER INFORMATION:
Investor Relations: Media Relations:
Sandy Klugman Carolmarie C. Brown
+1 (302) 594-7777 +1 (302) 995-3158
[email protected] [email protected]
10
Ashland Inc. and Consolidated Subsidiaries
STATEMENTS OF CONSOLIDATED INCOME (LOSS)(In Table 1
millions except per share data - preliminary and
unaudited)
Thr…
mon… Year
end… end…
──────────────────────────────────────────────────────────────────────────────
Sep… Sep…
30 30
2026 2025 2026 2025
Sa… $ 498 $ 478 $ 1,8… $ 1,…
Co…
of 319 319 1,2… 1,…
sa…
GR… 179 159 601 549
PR…
Se…
ge…
and 113 76 377 344
ad…
ex…
Re…
and 14 13 55 54
de…
ex…
In…
am… 14 15 60 63
ex…
Eq…
and 2 2 4 4
ot…
in…
Go… - - - 706
im…
(L…
in…
on (11 ) 4 (8 ) (1… )
di…
net
OP…
IN… 29 61 105 (7… )
(L…
Net
in…
and 21 - 40 33
ot…
ex…
Ot…
net
pe… (1 ) (3 ) (4 ) 1
be…
(i…
lo…
IN…
(L…
FR…
CO…
OP…
BE…
IN… 9 64 69 (8… )
TA…
In…
tax 26 31 44 13
ex…
(L…
IN…
FR… (17 ) 33 25 (8… )
CO…
OP…
In…
(l…
fr…
di…
op… 1 (1 ) (21 ) (23 )
net
of
in…
ta…
NET
(L… $ (16 ) $ 32 $ 4 $ (8… )
IN…
DI…
EA…
(L…
PER
SH…
(L…
in…
fr… $ (0.… ) $ 0.73 $ 0.55 $ (1… )
co…
op…
In…
(l…
fr… 0.01 (0.… ) (0.… ) (0… )
di…
op…
Net
(l… $ (0.… ) $ 0.71 $ 0.09 $ (1… )
in…
AV…
DI…
CO… 46 46 46 46
SH…
OU…
SA…
Li… 180 173 671 641
Sc…
Pe… 163 151 592 577
Ca…
Sp… 131 131 504 511
Ad…
In… 33 33 135 137
In… (9 ) (10 ) (39 ) (42 )
sa…
$ 498 $ 478 $ 1,8… $ 1,…
OP…
IN…
(L…
Li… 33 39 131 (2… )
Sc…
Pe… 35 26 101 90
Ca…
Sp… 1 5 (12 ) (3… )
Ad…
In… 4 2 11 8
Un…
and (44 ) (11 ) (126 ) (2… )
ot…
$ 29 $ 61 $ 105 $ (7… )
(a) Zero denotes less than $1 million of activity. (b) As a result of the loss
from continuing operations for both the three months ended September 30, 2026
and year ended September 30, 2025, the effect of the share-based awards
convertible to common shares would be anti-dilutive. In accordance with U.S.
GAAP, these shares have been excluded from the diluted earnings (loss) per share
calculation for the period.
11
Ashland Inc. and Consolidated Subsidiaries
CONDENSED CONSOLIDATED BALANCE SHEETS(In millions Table 2
- preliminary and unaudited)
ASSETS September 30 September 30
Current assets 2026 2025
──────────────────────────────────────────────────────────────────────────────
Cash and cash equivalents $ 480 $ 215
Accounts receivable, net 266 242
Inventories 482 568
Other assets 108 180
Total current assets 1,336 1,205
Noncurrent assets
Property, plant and
equipment
Cost 3,304 3,355
Accumulated depreciation 2,170 2,154
Net property, plant and 1,134 1,201
equipment
Goodwill 698 705
Intangibles, net 498 563
Operating lease assets, net 99 103
Restricted investments 248 297
Asbestos insurance 137 127
receivable, net
Deferred income taxes 138 157
Other assets 239 253
Total noncurrent assets 3,191 3,406
Total assets $ 4,527 $ 4,611
LIABILITIES AND EQUITY
Current liabilities
Trade and other payables $ 210 $ 189
Accrued expenses and other 220 213
liabilities
Current portion of long-term 4 -
debt
Current operating lease 18 21
obligations
Total current liabilities 452 423
Noncurrent liabilities
Long-term debt 1,367 1,384
Asbestos litigation reserves 385 389
Deferred income taxes 24 31
Employee benefit obligations 77 96
Operating lease obligations 83 85
Other liabilities 291 299
Total noncurrent liabilities 2,227 2,284
Equity 1,848 1,904
Total liabilities and equity $ 4,527 $ 4,611
12
Ashland Inc. and Consolidated Subsidiaries
STATEMENTS OF CONSOLIDATED CASH FLOWS(In millions Table 3
- preliminary and unaudited)
Thr…
mon… Year
end… ended
──────────────────────────────────────────────────────────────────────────────
Sep… Sept…
30 30
2026 2025 2026 2025
CASH
FLO…
PRO…
BY
OPE…
ACT…
FROM
CON…
OPE…
Net
(lo… $ (16 ) $ 32 $ 4 $ (845 )
inc…
(In…
loss
from
dis…
ope… (1 ) 1 21 23
net
of
inc…
tax…
Adj…
to
rec…
(lo…
inc…
from
con…
ope…
to
cash
flo…
from
ope…
act…
Dep…
and 45 50 185 237
amo…
Ori…
iss…
dis…
and 2 2 8 7
debt
iss…
cost
amo…
Def…
inc… 3 68 7 73
tax…
Gain
from
sal…
of (3 ) (5 ) (5 ) (16 )
pro…
pla…
and
equ…
Equ…
inc… - - (1 ) -
from
aff…
Sto…
bas… 5 2 18 14
com…
exp…
Loss
from
exc…
tax
ded… - (3 ) (1 ) (3 )
on
sto…
bas…
com…
Inc…
(lo…
from 7 (17 ) (21 ) (33 )
res…
inv…
Loss
on 13 2 13 177
div…
net
Goo… - - - 706
imp…
Ass… 18 - 18 -
imp…
Pen… (3 ) (3 ) (12 ) (12 )
con…
Gain
on
pen…
and (2 ) (4 ) (7 ) (3 )
oth…
pos…
plan
rem…
Cha…
in
ope… 22 (85 ) 158 (191 )
ass…
and
lia…
Tot…
cash
flo…
pro…
by 90 40 385 134
ope…
act…
from
con…
ope…
CASH
FLO…
PRO…
(US…
BY
INV…
ACT…
FROM
CON…
OPE…
Add…
to
pro… (37 ) (34 ) (88 ) (98 )
pla…
and
equ…
Pro…
from
dis…
of 2 5 6 16
pro…
pla…
and
equ…
Pro…
from
sale - - 2 16
of
ope…
Pro…
from
set…
of 2 7 27 12
Com…
life
ins…
con…
Com…
life (3 ) (3 ) (4 ) (5 )
ins…
pay…
Fun…
res…
for - - (9 ) (8 )
spe…
tra…
Rei…
from 22 21 74 62
res…
inv…
Pro…
from
sale 31 20 71 56
of
sec…
Pur…
of (31 ) (18 ) (71 ) (54 )
sec…
Tot…
cash
flo…
pro…
(us…
by (14 ) (2 ) 8 (3 )
inv…
act…
from
con…
ope…
CASH
FLO…
USED
BY
FIN…
ACT…
FROM
CON…
OPE…
Rep…
of - - - (100 )
com…
sto…
Debt
iss… - - (2 ) -
cos…
Cash
div… (19 ) (19 ) (76 ) (76 )
paid
Sto…
bas…
com…
emp…
wit… (2 ) - (3 ) (3 )
tax…
paid
in
cash
Tot…
cash
flo…
used
by (21 ) (19 ) (81 ) (179 )
fin…
act…
from
con…
ope…
CASH
PRO…
(US… 55 19 312 (48 )
BY
CON…
OPE…
Cash
used
by
dis…
ope…
Ope…
cash (15 ) (13 ) (46 ) (40 )
flo…
Eff…
of
cur…
exc…
rate
cha… - 2 (1 ) 3
on
cash
and
cash
equ…
INC…
(DE…
IN
CASH 40 8 265 (85 )
AND
CASH
EQU…
CASH
AND
CASH
EQU… 440 207 215 300
-
BEG…
OF
PER…
CASH
AND
CASH
EQU… $ 480 $ 215 $ 480 $ 215
-
END
OF
PER…
DEP…
AND
AMO…
Life 14 14 56 75
Sci…
Per… 14 16 60 65
Care
Spe… 15 17 63 84
Add…
Int… 2 3 5 13
Una…
and - - 1 -
oth…
$ 45 $ 50 $ 185 $ 237
(a) Excludes changes resulting from operations sold. (b) Zero denotes less than
$1 million of activity.
13
Ashland Inc. and Consolidated Subsidiaries
RECONCILIATION OF NON-GAAP DATA - ADJUSTED Table 4
EBITDA(In millions - preliminary and unaudited)
Three months ended
Adjusted EBITDA - Ashland September 30
Inc. 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net (loss) income $ (16 ) $ 32
Income tax expense 26 31
Net interest and other 21 -
income
Depreciation and 45 49
amortization(a)
EBITDA 76 112
(Income) loss from
discontinued (1 ) 1
operations, net of income
taxes
Gain on pension and other
postretirement (2 ) (4 )
plan remeasurements
Operating key items (see 48 10
Table 5)
Adjusted EBITDA $ 121 $ 119
Adjusted EBITDA - Life
Sciences
Operating income $ 33 $ 39
Add:
Depreciation and 14 14
amortization
Operating key items (see 17 2
Table 5)
Adjusted EBITDA $ 64 $ 55
Adjusted EBITDA - Personal
Care
Operating income $ 35 $ 26
Add:
Depreciation and 14 15
amortization(a)
Operating key items (see - 2
Table 5)
Adjusted EBITDA $ 49 $ 43
Adjusted EBITDA -
Specialty Additives
Operating income $ 1 $ 5
Add:
Depreciation and 15 17
amortization
Operating key items (see 4 7
Table 5)
Adjusted EBITDA $ 20 $ 29
Adjusted EBITDA -
Intermediates
Operating income $ 4 $ 2
Add:
Depreciation and 2 3
amortization
Adjusted EBITDA $ 6 $ 5
(a) Depreciation and amortization excludes accelerated depreciation expense of
$1 million for Personal Care for the three months ended September 30, 2025,
which is included as a key item within this table as a component of Adjusted
EBITDA.
14
Ashland Inc. and Consolidated Subsidiaries SEGMENT
COMPONENTS OF KEY ITEMS FOR APPLICABLE Table 5
CONSOLIDATED INCOME (LOSS) STATEMENT CAPTIONS(In
millions - preliminary and unaudited)
…
…
…
…
…
…
──────────────────────────────────────────────────────────────────────────────
… … … U…
… … … … a… T…
o…
…
…
…
…
…
…
… $ (… ) $ - $ (2 ) $ - $ - $ … )
…
…
…
… - - - - … ) … )
…
…
…
…
… - - - - … ) … )
…
…
…
… - - - - … ) … )
…
…
… (1 ) - (2 ) - - … )
…
…
…
…
… 50 35 5 4 … ) …
…
…
…
… 33 35 1 4 … ) …
…
…
…
…
…
…
… 9 9
…
…
…
…
… … …
…
…
…
… …
…
…
…
…
…
… … ) … )
…
…
…
… 1 1
…
…
…
… ) … )
…
…
…
…
…
… … ) … )
…
…
…
… 7 7
…
…
…
…
… … …
…
…
… …
…
…
… $ 33 $ 35 $ 1 $ 4 $ … ) $ … )
…
…
…
…
…
…
…
…
──────────────────────────────────────────────────────────────────────────────
… … … U…
… … … … a… T…
o…
$ … ) $ … ) $ (7 ) $ - $ - $ … )
- - - - … ) … )
- - - - … ) … )
- - - - … ) … )
- … ) - - - … )
- - - - 3 3
- - - - 4 4
… … 12 2 … ) …
… … 5 2 … ) …
… ) … )
… …
- -
… ) … )
1 1
… ) … )
2 2
… …
… …
… …
$ … $ … $ 5 $ 2 $ … ) $ …
(a) Represents the tax effect of the key items that are previously identified
above. (b) Represents key items resulting from tax specific financial
transactions, tax law changes or other matters that fall within the definition
of tax specific key items. See Table 7 for additional information.
15
Ashland Inc. and Consolidated Subsidiaries
RECONCILIATION OF CERTAIN NON-GAAP DATA(In Table 6
millions - preliminary and unaudited)
Thr…
mon… Year
end… end…
──────────────────────────────────────────────────────────────────────────────
Sep… Sep…
30 30
Fr…
ca… 2026 2025 2026 2025
fl…
To…
ca…
fl…
pr…
by $ 90 $ 40 $ 385 $ 134
op…
ac…
fr…
co…
op…
Ad…
Ad…
to
pr… (37 ) (34 ) (88 ) (98 )
pl…
and
eq…
Fr…
Ca… $ 53 $ 6 $ 297 $ 36
Fl…
Tax - - (103 ) -
re…
Ca…
(i…
ou…
fr…
U.… - 1 (9 ) 12
Ac…
Re…
Sa…
Pr…
Ca…
(i…
ou…
fr…
Fo… 3 19 (9 ) 6
Ac…
Re…
Sa…
Pr…
Re… 6 11 23 34
pa…
En…
and
re… 12 15 33 39
li…
pa…
On…
Fr… $ 74 $ 52 $ 232 $ 127
Ca…
Fl…
Net
(l… $ (16 ) $ 32 $ 4 $ (8… )
in…
Ad… $ 121 $ 119 $ 385 $ 401
EB…
Op…
Ca… Not 125 % 9,6… % Not
Fl… mea… mea…
Co…
On…
Fr…
Ca… 61 % 44 % 60 % 32 %
Fl…
Co…
(a) Represents receipt of tax refund related to the capital loss carryback from
the Nutraceutical business sale. (b) Represents activity associated with the
U.S. Accounts Receivable Sales Program impacting each period presented. (c)
Represents activity associated with the Foreign Accounts Receivable Sales
Program impacting each period presented. (d) Restructuring payments incurred
during each period presented. (e) Represents cash outflows associated with
environmental and related litigation payments which will be reimbursed by the
Environmental trust. (f) See Adjusted EBITDA reconciliation. (g) Operating Cash
Flow Conversion is defined as Cash flows provided by operating activities from
continuing operations divided by net (loss) income. (h) Ongoing Free Cash Flow
Conversion is defined as Ongoing Free Cash Flow divided by Adjusted EBITDA.
Three
months Year
ended ended
──────────────────────────────────────────────────────────────────────────────
Septe… Sept…
30 30
Adju…
Oper… 2026 2025 2026 2025
Inco…
Oper…
inco…
(los… $ 29 $ 61 $ 105 $ (775 )
(as
repo…
Key
item…
befo…
tax:
Envi…
rese… 5 1 33 34
adju…
Rest…
sepa…
and 9 4 23 22
other
costs
Other
plant 3 10 21 22
opti…
costs
Asset 18 - 18 -
impa…
Arge…
liqu…
cumu… 13 - 13 -
tran…
adju…
Acce… - 1 5 41
depr…
Good… - - - 706
impa…
Avoca
busi…
impa… - - - 175
and
sale
Nutr…
busi…
impa… - 1 - 1
and
sale
Held
for
sale - - - (2 )
depr…
and
amor…
Inco…
on - (4 ) (2 ) (14 )
dive…
net
Tax - (3 ) (8 ) (3 )
cred…
Adju…
Oper… $ 77 $ 71 $ 208 $ 207
Inco…
(non…
16
Ashland Inc. and Consolidated Subsidiaries
RECONCILIATION OF CERTAIN NON-GAAP DATA(In Table 7
millions except per share data - preliminary and
unaudited)
Thr…
mon… Year
end… end…
──────────────────────────────────────────────────────────────────────────────
Sep… Sep…
30 30
2026 2025 2026 2025
(L…
in…
fr…
co… $ (17 ) $ 33 $ 25 $ (822 )
op…
(as
re…
Key
it…
be…
ta…
En…
re… 5 1 33 34
ad…
Re…
se…
and 9 4 23 22
ot…
co…
Ot…
pl… 3 10 21 22
op…
co…
As… 18 - 18 -
im…
Ar…
li…
cu… 13 - 13 -
tr…
ad…
Ac… - 1 5 41
de…
Go… - - - 706
im…
Av…
bu…
im… - - - 175
and
sa…
Nu…
bu…
im… - 1 - 1
and
sa…
He…
for
sa… - - - (2 )
de…
and
am…
In…
on - (4 ) (2 ) (14 )
di…
net
Tax - (3 ) (8 ) (3 )
cr…
Un…
(g…
lo… 9 (15 ) (9 ) (20 )
on
se…
Ga…
on
pe…
and (2 ) (4 ) (7 ) (3 )
ot…
po…
pl…
re…
Key
it… 55 (9 ) 87 959
be…
tax
Tax
ef…
of (4 ) 2 (14 ) (62 )
key
it…
Key
it… 51 (7 ) 73 897
af…
tax
Tax
sp…
key
it…
Va… 7 8 7 9
al…
Ot…
and
tax - 3 - 22
re…
re…
ac…
Tax
sp… 7 11 7 31
key
it…
To…
key 58 4 80 928
it…
Ad…
In…
fr… $ 41 $ 37 $ 105 $ 106
Co…
Op…
(n…
In…
am…
ex…
ad… 11 13 48 51
(n…
of
ta…
Ad…
In…
fr…
Co…
Op… $ 52 $ 50 $ 153 $ 157
(n…
Ex…
In…
Am…
Ex…
(a) Represents the tax effect of the key items that are previously identified
above. (b) Represents key items resulting from tax specific financial
transactions, tax law changes or other matters that fall within the definition
of tax specific key items. These tax specific key items included the following:
- Valuation allowance: Includes the impact from the release of certain foreign
tax credit valuation allowances. - Other and tax reform: Includes the impact
from the remeasurement of foreign deferred tax balances resulting from the
impact from rate changes for foreign jurisdictions and other tax law changes
enacted during the year ended September 30, 2025. (c) Intangibles amortization
expense adjustment (net of tax) tax rates were 20% for the three months and
years ended September 30, 2026 and 2025.
17
Ashland Inc. and Consolidated Subsidiaries
RECONCILIATION OF CERTAIN NON-GAAP DATA(In Table 7 (Continued)
millions except per share data - preliminary and
unaudited)
Thr…
mon… Year
end… end…
──────────────────────────────────────────────────────────────────────────────
Sep… Sep…
30 30
2026 2025 2026 2025
Di…
EPS
fr…
co… $ (0.… ) $ 0.… $ 0.… $ (1… )
op…
(as
re…
Key
it…
be…
ta…
En…
re… 0.11 0.… 0.… 0.…
ad…
Re…
se…
and 0.20 0.… 0.… 0.…
ot…
co…
Ot…
pl… 0.06 0.… 0.… 0.…
op…
co…
As… 0.38 - 0.… -
im…
Ar…
li…
cu… 0.28 - 0.… -
tr…
ad…
Ac… - 0.… 0.… 0.…
de…
Go… - - - 15…
im…
Av…
bu…
im… - - - 3.…
and
sa…
Nu…
bu…
im… - 0.… - 0.…
and
sa…
He…
for
sa… - - - (0… )
de…
and
am…
In…
on - (0… ) (0… ) (0… )
di…
net
Tax - (0… ) (0… ) (0… )
cr…
Un…
(g…
lo… 0.20 (0… ) (0… ) (0… )
on
se…
Ga…
on
pe…
and (0.… ) (0… ) (0… ) (0… )
ot…
po…
pl…
re…
Key
it… 1.18 (0… ) 1.… 20…
be…
tax
Tax
ef…
of (0.… ) 0.… (0… ) (1… )
key
it…
Key
it… 1.10 (0… ) 1.… 19…
af…
tax
Tax
sp…
key
it…
Va… 0.15 0.… 0.… 0.…
al…
Ot…
and
tax - 0.… - 0.…
re…
re…
ac…
Tax
sp… 0.15 0.… 0.… 0.…
key
it…
To…
key 1.25 0.… 1.… 20…
it…
Ad…
Di…
EPS
fr… $ 0.89 $ 0.… $ 2.… $ 2.…
Co…
Op…
(n…
In…
am…
ex…
ad… 0.23 0.… 1.… 1.…
(n…
of
ta…
Ad…
Di…
EPS
fr…
Co…
Op… $ 1.12 $ 1.… $ 3.… $ 3.…
(n…
Ex…
In…
Am…
Ex…
(a) Represents the tax effect of the key items that are previously identified
above. (b) Represents key items resulting from tax specific financial
transactions, tax law changes or other matters that fall within the definition
of tax specific key items. These tax specific key items included the following:
- Valuation allowance: Includes the impact from the release of certain foreign
tax credit valuation allowances. - Other and tax reform: Includes the impact
from the remeasurement of foreign deferred tax balances resulting from the
impact from rate changes for foreign jurisdictions and other tax law changes
enacted during the year ended September 30, 2025. (c) Intangibles amortization
expense adjustment (net of tax) tax rates were 20% for the three months and
years ended September 30, 2026 and 2025.
18
Ashland Inc. and Consolidated Subsidiaries
RECONCILIATION OF CERTAIN NON-GAAP DATA(In Table 8
millions - preliminary and unaudited)
Year ended
──────────────────────────────────────────────────────────────────────────────
September 30
Adjusted EBITDA - Ashland Inc. 2026 2025
Net income (loss) $ 4 $ (845 )
Income tax expense 44 13
Net interest and other expense 40 33
Depreciation and 180 198
amortization(a)
EBITDA 268 (601 )
Income (loss) from discontinued 21 23
operations, net of income taxes
Key items included in EBITDA:
Environmental reserve 33 34
adjustments
Restructuring, separation and
other 23 22
costs
Other plant optimization costs 21 22
Asset impairments 18 -
Argentina liquidation
cumulative 13 -
translation adjustment
Accelerated depreciation 5 41
Goodwill impairment - 706
Avoca business impairment and - 175
sale
Nutraceutical business
impairment and - 1
sale
Held for sale depreciation and - (2 )
amortization
Income on divestitures, net (2 ) (14 )
Tax credit (8 ) (3 )
Gain on pension and other
postretirement (7 ) (3 )
plan remeasurements(b)
Adjusted EBITDA(b) $ 385 $ 401
(a) Depreciation and amortization excludes accelerated depreciation of $21
million for Life Sciences for the year ended September 30, 2025, $1 million for
Personal Care for the year ended September 30, 2026, $3 million and $19 million
for Specialty Additives for the years ended September 30, 2026 and 2025,
respectively, and $1 million for Unallocated and other for the year ended
September 30, 2026, which are included as a key item within this table as a
component of Adjusted EBITDA. Depreciation and amortization includes $2 million
for Personal Care associated with the Avoca business for the year ended
September 30, 2025, which is included as a key item within this table as a
component of Adjusted EBITDA. (b) Includes $5 million and $7 million of net
periodic loss recognized ratably through the years ended September 30, 2026 and
2025, respectively. These costs are comprised of service cost, interest cost,
expected return on plan assets, and amortization of prior service credit.
19
20